



ELSEVIER

Contents lists available at ScienceDirect

Phytomedicine

journal homepage: www.elsevier.com/locate/phymed

Activity of *Artemisia annua* and artemisinin derivatives, in prostate carcinoma



Friedrich-Wilhelm Michaelsen^{a,1}, Mohamed E.M. Saeed^b, Jörg Schwarzkopf^c,
Thomas Efferth^{b,*}

^a Practice for Naturopathy, 29499 Zernien, Germany

^b Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany

^c Clinic for General Medicine, 29456 Hitzacker, Germany

DISEASE: Human prostate carcinoma

LOCATION: Germany

STUDY SUBJECT: One 80 year old man

TREATMENT: *A. annua* capsules (5x50 mg/day) long term (following short term treatment with bicalitumide)

RESULT: combined with the short-term treatment, “**resulted in considerable regression of advanced metastasized prostate carcinoma**”

QUOTING THEIR CONCLUSION: “Long-term treatment with *A. annua* capsules combined with short-term bicalitumide **treatment resulted in considerable regression** of advanced metastasized prostate carcinoma. Controlled clinical trials are required to evaluate the clinical benefit of *A. annua* in prostate cancer.”

LINK:

<https://www.sciencedirect.com/science/article/pii/S0944711315003323?via%3Dihub>

Phytomedicine 62 (2019) 152962

Contents lists available at ScienceDirect

Phytomedicine


journal homepage: www.elsevier.com/locate/phymed

Original Article

Antitumor activity of an *Artemisia annua* herbal preparation and identification of active ingredients

Sophia J. Lang^a, Michael Schmiech^a, Susanne Hafner^a, Christian Paetz^b, Carmen Steinborn^c, Roman Huber^c, Menna El Gaafary^{a,d}, Katharina Werner^a, Christoph Q. Schmidt^a, Tatiana Syrovets^a, Thomas Simmet^{a,*}

^a Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, 89081 Ulm, Germany
^b Max Planck Institute for Chemical Ecology, 07745 Jena, Germany
^c Center for Complementary Medicine, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany
^d Department of Pharmacognosy, College of Pharmacy, Cairo University, Cairo 11562, Egypt



DISEASE: Triple-negative breast cancer

LOCATION: Germany

STUDY SUBJECTS: Cell and Mouse-Xenograph study

TREATMENT: Artemisia annua aqueous and acetonitrile-treated extract

RESULT: The *Artemisia annua* extract was found to be cytotoxic to a variety of treatment-resistant cancer cell lines derived from different tissues, although with different sensitivity, in both cells and mice. **Daily treatment of mice with xenografted breast cancer for 3 weeks slowed tumor growth to a similar extent as the standard chemotherapeutic doxorubicin.** Doxorubicin is highly toxic, resulting in body weight loss in mice – **this was not observed in mice**, where overall **much lower systemic toxicity was observed.**

QUOTING THEIR CONCLUSION: “This study provides evidence for an **anticancer activity of an *Artemisia annua* extract** marketed as a herbal preparation. Together, the results reveal new insights of *Artemisia annua*-derived compounds, their potential efficacy in anticancer therapy, and uncover compounds beside with **activity against highly metastatic triple negative human breast cancer cells** that are different from artemisinin. In addition, the study provides evidence for therapeutically active compounds in a herbal preparation. **These findings justify further exploration** of these compounds for therapeutic purposes.”



LINK: <https://www.sciencedirect.com/science/article/pii/S094471131930131X>

Phytomedicine 52 (2019) 247–253

Contents lists available at ScienceDirect

Phytomedicine


journal homepage: www.elsevier.com/locate/phymed



Dried leaf *Artemisia annua* efficacy against non-small cell lung cancer

Dina J. Rassias^a, Pamela J. Weathers^{b,*}

^a Department of Biomedical Engineering, Worcester Polytechnic Institute, United States
^b Department of Biology and Biotechnology, Worcester Polytechnic Institute, Worcester, MA 01609 United States



DISEASE: Non-Small Cell Lung Cancer

LOCATION: USA

STUDY SUBJECTS: Cell and Mouse-Xenograph study

TREATMENT: Artemisia annua aqueous and acetonitrile-treated extract

RESULT: Dried leaf **Artemisia annua suppressed cancer cell viability** with no inhibition of healthy human cells and **inhibited cancer cell migration**. In the mouse xenographs, *A. annua* treatment resulted in **inhibited tumor growth by 50%** compared to controls.

QUOTING THEIR CONCLUSION: “To our knowledge this is the first study showing dried leaf **Artemisia annua (DLA) inhibited tumor growth**. Using DLAE to study mechanism, we showed that DLAE is cytotoxic to human NSCLC cells and mechanistically similar to AS by **slowing proliferation**, stimulating cell cycle arrest and inducing apoptosis. DLAE also **inhibited migration** of A549 and PC9 NSCLC cells. Moreover, DLA inhibited A549 and PC9 induced tumor growth, whereas AS only inhibited A549 tumor growth. Together these results suggest **DLA is a novel therapeutic for possible treatment of NSCLC** and potentially other AN-sensitive cancers.”

LINK:

<https://www.sciencedirect.com/science/article/abs/pii/S0944711318304483?via%3Dihub>